ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
Press release – No. 5 / 2024
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
Copenhagen, Denmark, May 29, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Adam Steensberg, President and CEO, will participate in fireside chats at the following healthcare investor conferences in June:
Jefferies Global Healthcare Conference, June 4-6 in New York City
Wednesday, June 5 at 10:00 a.m. ET (4:00 p.m. CET)
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.